BeautyHealth Reports First Quarter 2025 Financial Results

Rhea-AI Summary

BeautyHealth (NASDAQ: SKIN) reported Q1 2025 financial results with net sales of $69.6 million, down 14.5% from Q1 2024, primarily due to lower delivery systems sales. Despite macroeconomic pressures, the company showed improved profitability metrics with gross margin increasing to 69.8% from 59.4% year-over-year. The company reported a net loss of $10.1 million compared to $0.7 million in Q1 2024, while Adjusted EBITDA improved to $7.3 million from $0.4 million. The active install base grew to 35,014 units from 32,530 in the prior year, supporting resilient consumables revenue. The company is transitioning its China operations to a distributor model and has updated its FY2025 guidance to $270-300 million in net sales and $15-25 million in Adjusted EBITDA.

Positive

• Gross margin improved significantly to 69.8% from 59.4% year-over-year
• Adjusted EBITDA increased to $7.3 million from $0.4 million in Q1 2024
• Active install base grew to 35,014 units from 32,530 year-over-year
• Consumables net sales showed resilience, increasing to $49.4M from $45.6M
• Strong cash position with $373.0 million in cash and equivalents

Negative

• Net sales declined 14.5% year-over-year to $69.6 million
• Net loss increased to $10.1 million from $0.7 million in Q1 2024
• Delivery systems sales dropped significantly to $20.2M from $35.8M
• Total delivery systems sold decreased to 862 units from 1,417 year-over-year

Insights

Financial Analyst

BeautyHealth pivots to profitable recurring revenue model amid device sales weakness, with 18x EBITDA growth despite revenue decline.

BeautyHealth's Q1 2025 results reveal a significant business transformation in progress. While total revenue declined 14.5% to $69.6 million, this masks an important shift in business composition. The company's recurring consumables revenue grew 8.3% to $49.4 million, now representing 71% of total revenue compared to 56% in Q1 2024. This shift toward predictable, higher-margin revenue explains the substantial gross margin expansion from 59.4% to 69.8%.

Delivery systems sales declined sharply (862 units vs 1,417 prior year), with the most pronounced drop in APAC where unit sales fell by 70% (98 vs 327). However, the active install base continues to grow, reaching 35,014 units, supporting the consumables growth narrative.

Most impressive is the company's operational efficiency improvements. Despite lower revenue, adjusted EBITDA increased approximately 18-fold to $7.3 million from $0.4 million, with margins expanding from 0.4% to 10.4%. This reflects both successful cost control and the higher proportion of recurring, high-margin consumables revenue.

The net loss of $10.1 million (compared to $0.7 million in Q1 2024) requires context - the prior year benefited from a one-time gain on convertible note repurchases.

Strategic initiatives to relocate production to the US (mitigating tariff risk) and transition China to a distributor model demonstrate prioritization of long-term profitability over short-term growth. With $373 million in cash and restricted cash, BeautyHealth maintains financial flexibility to execute these transitions.

The updated 2025 guidance of $270-300 million in revenue and $15-25 million in adjusted EBITDA acknowledges continued device sales pressure but reflects confidence in sustained profitability improvements through cost optimization and the shift to a more favorable revenue mix.

LONG BEACH, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- The Beauty Health Company (NASDAQ: SKIN) (“BeautyHealth” or the "Company"), home to flagship brand Hydrafacial, today announced financial results for the first quarter ended March 31, 2025 (“Q1 2025”).

“Our first quarter results reflect strong execution and continued momentum in our transformation strategy,” said CEO Marla Beck. “We exceeded both revenue and adjusted EBITDA guidance, driven by gross profit growth and meaningful cost efficiencies. Despite macroeconomic pressures that impacted device sales, consumables revenue remained resilient, reinforcing the strength of our recurring revenue model and sustained consumer demand.”

“We have taken decisive actions to expand profit margins and drive shareholder value—relocating production to the U.S. to mitigate tariff risk and initiating the transition of our China operations to a distributor model. With a pipeline of impactful product launches and bold brand initiatives ahead, we believe we are well-positioned to deepen provider engagement, elevate consumer loyalty, and return the Company to sustainable long-term growth.”

Key Operational and Business Metrics

	Three Months Ended March 31,
Unaudited ($ in millions) (1)		2025				2024
Delivery Systems net sales	$	20.2			$	35.8
Consumables net sales		49.4				45.6
Total net sales	$	69.6			$	81.4
Gross profit	$	48.6			$	48.4
Gross margin		69.8	%			59.4	%
Adjusted gross profit(2)	$	50.0			$	51.6
Adjusted gross margin(2)		71.9	%			63.4	%
Net loss	$	(10.1	)		$	(0.7	)
Adjusted EBITDA(2)	$	7.3			$	0.4
Adjusted EBITDA margin(2)		10.4	%			0.4	%

	Three Months Ended March 31,
Unaudited	2025		2024
Total delivery systems sold	862		1,417
Active install base(3)	35,014		32,530

__________________________
(1) Amounts may not sum due to rounding.
(2) See "Non-GAAP Financial Measures" below.
(3) Estimated number of delivery systems owned by providers that have purchased consumables in the trailing twelve-month period.

BeautyHealth completed the first quarter of 2025 with an estimated active install base of 35,014 units, as compared to 32,530 in the prior year, resulting in growth in consumable net sales. The decrease in overall revenue resulted from fewer units placed year over year, impacted by a challenging macroeconomic environment. The Company continues to evaluate its strategic footprint and is transitioning its China market from a direct sales to distributor model in the second quarter of 2025.

First Quarter Financial Highlights

• Net sales were $69.6 million for the first quarter of 2025, a decrease of (14.5)%, compared to the prior year period ("Q1 2024"), due to lower delivery systems net sales.
• Gross margin was 69.8% in Q1 2025 compared to 59.4% in Q1 2024. Adjusted gross margin was 71.9% in Q1 2025 compared to 63.4% in Q1 2024. The improvement in gross margin and adjusted gross margin was primarily due to lower inventory related charges and favorable mix shift towards consumable net sales, partially offset by lower average selling price of equipment net sales.
• Net loss was $(10.1) million in Q1 2025 compared to $(0.7) million in Q1 2024. The change compared to the prior year was primarily due to the gain on repurchase of $75.0 million of principal amount of the Company's convertible senior notes in Q1 2024 and lower net sales, partially offset by lower operational spend and higher gross margin.
• Adjusted EBITDA was $7.3 million in Q1 2025 compared to $0.4 million in Q1 2024. The improvement in adjusted EBITDA was primarily due to lower operational spend and higher gross margin, partially offset by lower net sales.
• The Company placed 862 delivery systems during Q1 2025 compared to 1,417 during Q1 2024, reflecting a challenging macroeconomic environment.
  

Balance Sheet and Cash Flow Highlights

• Cash, cash equivalents, and restricted cash were approximately $373.0 million as of March 31, 2025 compared to approximately $370.1 million as of December 31, 2024.
• The Company had approximately 7 million private placement warrants and approximately 125.2 million shares of Class A common stock outstanding as of March 31, 2025.

Updated 2025 Financial Guidance

Second Quarter 2025
Net sales	$71 – $76 million
Adjusted EBITDA(1)	$2 – $4 million
Fiscal Year 2025
Net sales	$270 – $300 million
Adjusted EBITDA(1)	$15 – $25 million

__________________________
(1) See "Non-GAAP Financial Measures" below.

Updated 2025 financial guidance reflects the following assumptions:

• Net sales guidance reflects continued downward pressure on delivery systems net sales.
• Assumes no material deterioration in current general market conditions or other unforeseen circumstances beyond the Company's control, such as foreign currency exchange rates, tariffs, and trade restrictions.
• Excludes any unannounced acquisitions, dispositions or financings.
  

Regional Operational and Business Metrics

	Three Months Ended March 31,
Unaudited ($ in millions) (1)		2025			2024
Delivery Systems net sales
Americas	$	13.1		$	18.3
Asia-Pacific (“APAC”)		2.0			7.5
Europe, the Middle East and Africa (“EMEA”)		5.1			10.0
Total Delivery Systems net sales	$	20.2		$	35.8
Consumables net sales
Americas	$	33.1		$	32.0
APAC		6.4			4.5
EMEA		9.9			9.1
Total Consumables net sales	$	49.4		$	45.6
Net sales
Americas	$	46.3		$	50.3
APAC		8.3			12.0
EMEA		15.0			19.1
Total net sales	$	69.6		$	81.4
Delivery Systems sold
Americas		550			708
APAC		98			327
EMEA		214			382
Total Delivery Systems sold		862			1,417

__________________________
(1) Amounts may not sum due to rounding.

Conference Call

BeautyHealth will host a conference call on Thursday, May 8, 2025, at 4:30 p.m. ET to review its first quarter 2025 financial results. The call may be accessed via live webcast through the Events & Presentations page on our Investor Relations website at https://investors.beautyhealth.com. A replay of the conference call will be available approximately three hours after the conclusion of the call and can be accessed online at https://investors.beautyhealth.com.

Non-GAAP Financial Measures

In addition to results determined in accordance with accounting principles generally accepted in the United States of America ("GAAP"), management utilizes certain non-GAAP financial measures such as adjusted gross profit, adjusted gross margin, adjusted EBITDA, and adjusted EBITDA margin for purposes of evaluating ongoing operations and for internal planning and forecasting purposes.

Management believes that these non-GAAP financial measures, when reviewed collectively with the Company’s GAAP financial information, provide useful supplemental information to investors in assessing the Company's operating performance. These non-GAAP financial measures should not be considered as an alternative to GAAP financial information or as an indication of operating performance or any other measure of performance derived in accordance with GAAP, and may not provide information that is directly comparable to that provided by other companies in its industry, as these other companies may calculate non-GAAP financial measures differently, particularly related to unusual items.

Adjusted gross profit is gross profit excluding the effects of depreciation expense, amortization expense, and share-based compensation expense. Adjusted gross margin represents adjusted gross profit as a percentage of net sales.

Adjusted EBITDA is calculated as net loss excluding the effects of expense (benefit) for income taxes; depreciation expense; amortization expense; share-based compensation expense; interest expense; interest income; other income, net; change in fair value of warrant liabilities; foreign currency (gain) loss, net; litigation related costs; Go-to-Market restructuring; and severance, restructuring and other. Adjusted EBITDA margin represents adjusted EBITDA as a percentage of net sales.

The Company does not provide a reconciliation of its fiscal 2025 adjusted EBITDA guidance to net loss, the most directly comparable forward looking GAAP financial measures, due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation, which cannot be done without unreasonable efforts, including adjustments that could be made for changes in fair value of warrant liabilities, integration and acquisition-related expenses, amortization expenses, non-cash share-based compensation, gains/losses on foreign currency, and other charges reflected in our reconciliation of historic numbers, the amount of which, based on historical experience, could be significant. The presentation of this financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. The Company's fiscal 2025 adjusted EBITDA guidance is merely an outlook and is not a guarantee of future performance. Stockholders should not rely or place an undue reliance on such forward-looking statements. See “Forward-Looking Statements” for additional information.

The Beauty Health Company Condensed Consolidated Statements of Comprehensive Loss (1) ($ in millions, except share and per share amounts) (Unaudited)
	Three Months Ended March 31,
		2025				2024
Net sales	$	69.6			$	81.4
Cost of sales		21.0				33.0
Gross profit		48.6				48.4
Operating expenses:
Selling and marketing		26.0				33.7
Research and development		1.0				2.8
General and administrative		33.6				28.9
Total operating expenses		60.6				65.4
Loss from operations		(12.0	)			(17.0	)
Interest expense		2.5				3.0
Interest income		(3.0	)			(5.4	)
Other income, net		(0.1	)			(16.1	)
Change in fair value of warrant liabilities		(0.3	)			1.5
Foreign currency transaction (gain) loss, net		(1.9	)			1.3
Loss before provision for income taxes		(9.2	)			(1.3	)
Income tax expense (benefit)		0.9				(0.7	)
Net loss		(10.1	)			(0.7	)
Comprehensive loss, net of tax:
Foreign currency translation adjustments		1.1				(1.0	)
Comprehensive loss	$	(9.0	)		$	(1.7	)
Net loss per share
Basic	$	(0.08	)		$	(0.01	)
Diluted	$	(0.08	)		$	(0.10	)
Weighted average common shares outstanding
Basic		125,079,470				123,120,426
Diluted		125,079,470				144,477,208

__________________________
(1)   Amounts may not sum due to rounding.

The Beauty Health Company Condensed Consolidated Balance Sheets (1) ($ in millions) (Unaudited)
	March 31, 2025				December 31, 2024
ASSETS
Current assets:
Cash, cash equivalents, and restricted cash	$	373.0			$	370.1
Accounts receivable, net		23.3				27.6
Inventories		65.6				69.1
Income tax receivable		0.3				0.8
Prepaid expenses and other current assets		7.2				9.5
Total current assets		469.4				477.1
Property and equipment, net		4.2				6.0
Right-of-use assets, net		12.5				13.6
Intangible assets, net		45.6				47.5
Goodwill		124.3				123.5
Deferred income tax assets, net		4.3				3.9
Other assets		13.6				14.1
TOTAL ASSETS	$	673.8			$	685.7
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	23.1			$	21.9
Accrued payroll-related expenses		14.5				17.6
Lease liabilities, current		5.1				5.1
Income tax payable		3.3				3.4
Other accrued expenses		16.7				20.0
Total current liabilities		62.8				68.2
Lease liabilities, non-current		9.6				10.8
Deferred income tax liabilities, net		0.4				0.4
Warrant liabilities		0.1				0.5
Convertible senior notes, net		553.0				552.2
Other long-term liabilities		1.8				1.8
TOTAL LIABILITIES	$	627.8			$	633.9
Stockholders’ equity:
Class A Common Stock	$	—			$	—
Additional paid-in capital		569.9				566.7
Accumulated other comprehensive loss		(5.8	)			(7.0	)
Accumulated deficit		(518.1	)			(508.0	)
Total stockholders’ equity	$	46.1			$	51.8
LIABILITIES AND STOCKHOLDERS’ EQUITY	$	673.8			$	685.7

__________________________
(1)   Amounts may not sum due to rounding.

The Beauty Health Company Condensed Consolidated Statement of Cash Flows (1) ($ in millions) (Unaudited)
	Three Months Ended March 31,
		2025				2024
Cash, cash equivalents, and restricted cash at beginning of period	$	370.1			$	523.0
Operating activities:
Net loss		(10.1	)			(0.7	)
Non-cash adjustments:		10.2				9.8
Change in operating assets and liabilities:
Accounts receivable		4.0				5.9
Inventories		3.8				(11.1	)
Prepaid expenses, other current assets, and income tax receivable		2.9				1.9
Accounts payable, accrued expenses, and income tax payable		(5.7	)			(20.8	)
Other, net		(2.0	)			(1.9	)
Net cash provided by (used for) operating activities		3.0				(16.9	)
Net cash used for investing activities		(1.1	)			(1.8	)
Net cash used for financing activities		(0.3	)			(58.6	)
Net change in cash, cash equivalents, and restricted cash		1.6				(77.3	)
Effect of foreign currency translation		1.4				(1.1	)
Cash, cash equivalents, and restricted cash at end of period	$	373.0			$	444.6

__________________________
(1)   Amounts may not sum due to rounding.

The following table reconciles gross profit to adjusted gross profit for the periods presented:

	Three Months Ended March 31,
Unaudited ($ in millions) (1)		2025				2024
Net sales	$	69.6			$	81.4
Gross profit	$	48.6			$	48.4
Gross margin		69.8	%			59.4	%
Adjusted to exclude the following:
Depreciation expense		0.2				0.5
Amortization expense		1.1				3.2
Share-based compensation expense		0.2				(0.4	)
Adjusted gross profit	$	50.0			$	51.6
Adjusted gross margin		71.9	%			63.4	%

__________________________
(1)   Amounts may not sum due to rounding.


The following table reconciles net loss to adjusted EBITDA for the periods presented:

	Three Months Ended March 31,
Unaudited ($ in millions) (1)		2025				2024
Net sales	$	69.6			$	81.4
Net loss	$	(10.1	)		$	(0.7	)
Adjusted to exclude the following:
Expense (benefit) for income taxes		0.9				(0.7	)
Depreciation expense		1.9				2.8
Amortization expense		4.3				5.9
Share-based compensation expense		3.5				6.6
Interest expense		2.5				3.0
Interest income		(3.0	)			(5.4	)
Other income, net		(0.1	)			(16.1	)
Change in fair value of warrant liabilities		(0.3	)			1.5
Foreign currency (gain) loss, net		(1.9	)			1.3
Litigation related costs		6.9				0.6
Go-to-Market restructuring		2.7				—
Severance, restructuring and other		—				1.5
Adjusted EBITDA	$	7.3			$	0.4
Adjusted EBITDA margin		10.4	%			0.4	%

__________________________
(1)   Amounts may not sum due to rounding.

About The Beauty Health Company

The Beauty Health Company (NASDAQ: SKIN) is a medtech meets beauty company delivering millions of skin health experiences every year that help consumers reinvent their relationship with their skin, bodies, and self-confidence. Our brands are pioneers: Hydrafacial™ in hydradermabrasion, SkinStylus™ in nanoneedling and microneedling, and Keravive™ in scalp health. Together, with our powerful global community of estheticians, partners, and consumers, we are personalizing skin health for all ages, genders, skin tones, and skin types. We are committed to being ever more mindful in how we conduct our business to positively impact our communities and the planet. Find a local provider at https://hydrafacial.com/find-a-provider/, and learn more at beautyhealth.com or LinkedIn.

Forward-Looking Statements

Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding The Beauty Health Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements.

These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside The Beauty Health Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.

Important factors that may affect actual results or outcomes include, among others: The Beauty Health Company’s ability to manage growth; The Beauty Health Company’s ability to execute its business plan; potential litigation involving The Beauty Health Company; changes in applicable laws or regulations; the possibility that The Beauty Health Company may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the U.S. Securities and Exchange Commission (the “SEC”) and in the Company’s subsequent filings with the SEC. There may be additional risks that the Company does not presently know of or that the Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. The Beauty Health Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Contacts
Investors: IR@beautyhealth.com 
Press: Press@beautyhealth.com

FAQ

What were BeautyHealth's (SKIN) Q1 2025 earnings results?

BeautyHealth reported Q1 2025 net sales of $69.6M (down 14.5% YoY), net loss of $10.1M, and Adjusted EBITDA of $7.3M. Gross margin improved to 69.8% from 59.4% year-over-year.

How many Hydrafacial delivery systems did SKIN sell in Q1 2025?

BeautyHealth sold 862 delivery systems in Q1 2025, down from 1,417 in Q1 2024, reflecting challenging macroeconomic conditions.

What is BeautyHealth's (SKIN) revenue guidance for 2025?

BeautyHealth expects FY2025 net sales of $270-300 million and Adjusted EBITDA of $15-25 million.

How many active Hydrafacial systems does BeautyHealth have installed?

BeautyHealth reported an active install base of 35,014 units as of Q1 2025, up from 32,530 in the prior year.

What changes is BeautyHealth making to its China operations?

BeautyHealth is transitioning its China market from a direct sales model to a distributor model in the second quarter of 2025.